Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20089 in ovarian and endometrial cancer
NCT06014190Phase 2Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mocertatug rezetecan in ovarian cancer, endometrial cancer (EC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), solid tumor, sponsored by Hansoh Pharmaceutical Group. Started Dec 2023; status: recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
ovarian cancerendometrial cancer (EC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)solid tumor
Beyond the preview
Go deeper on NCT06014190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014190.